Shopping Cart
- Remove All
- Your shopping cart is currently empty
AlbA-DCA, a conjugate of Albiziabioside A and a dichloroacetate acid subunit, markedly increases intracellular ROS, alleviates lactic acid accumulation in the tumor microenvironment, selectively kills cancer cells, and induces apoptosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | Inquiry | Backorder | |
500 mg | Inquiry | Backorder |
Description | AlbA-DCA, a conjugate of Albiziabioside A and a dichloroacetate acid subunit, markedly increases intracellular ROS, alleviates lactic acid accumulation in the tumor microenvironment, selectively kills cancer cells, and induces apoptosis. |
In vitro | AlbA-DCA exhibits cytotoxicity against MCF-7, HCT116, A375, 4T1, HBMEC, and LO2 cells (IC50s: 0.43 μM, 3.87 μM, 3.78 μM, 1.31 μM, 38.20 μM, and 53.14 μM, respectively). Treatment with AlbA-DCA (2 μM; 24 hours) induces apoptosis in MCF-7 cells, significantly up-regulating cytochrome c expression, down-regulating Bcl-2 expression, and enhancing caspase-9 expression. |
In vivo | AlbA-DCA (2 mg/kg; subcutaneous injection; every 2 days; for 2 weeks; nude mice) demonstrates significant antitumor efficacy, nearly completely inhibiting tumor progression with no observed mortality or significant changes in body weight. Additionally, AlbA-DCA exhibits no apparent toxicity in the liver and kidney, nor any major abnormalities in the heart, liver, spleen, lung, and kidney. |
Molecular Weight | 860.9 |
Formula | C43H67Cl2NO12 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.